Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
A Japan-based joint venture between Takeda Pharmaceutical and Teva Holdings aims to become a number one player in what it describes as the “off-patent drug” market, which combines generics and long-listed brand-name products, in 2020 or later, CEO and President…
To read the full story
Related Article
- Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
- There Will Be Consolidation in Japan Generic Space: Teva Exec
October 11, 2016
- CEO of Teva-Takeda JV Confident on Handling Both Long-Listed Brands, Generics
August 17, 2016
- Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
BUSINESS
- Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- SymBio Enrolls First Patient in US for PIII BCV Trial in Adenovirus Infection
March 18, 2026
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…